{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:57:16Z","timestamp":1793307436827,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00120-024-02511-3","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T14:29:20Z","timestamp":1739197760000},"page":"246-255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Aggressive Varianten und transdifferenziertes neuroendokrines Prostatakarzinom: Von der Diagnose zur Therapie","Aggressive variant prostate cancer and transdifferentiated neuroendocrine prostate cancer: from diagnosis to therapy"],"prefix":"10.1007","volume":"64","author":[{"given":"Gunhild","family":"von Amsberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Dyshlovoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Kaune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"2511_CR1","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","volume":"36","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal\u00a0R, Huang\u00a0J, Alumkal\u00a0JJ et\u00a0al (2018) Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A\u00a0Multi-institutional Prospective Study. J\u00a0Clin Oncol 36:2492\u20132503","journal-title":"J Clin Oncol"},{"key":"2511_CR2","doi-asserted-by":"crossref","unstructured":"Aggarwal RR, Costin D, Zhang J et\u00a0al (2021) BXCL701, first-in-class oral activator of systemic innate immunity pathway, combined with pembrolizumab (Keytruda) in men with metastatic castration-resistant prostate cancer (mCRPC). Am Soc Clin Oncol","DOI":"10.1200\/JCO.2021.39.6_suppl.124"},{"key":"2511_CR3","doi-asserted-by":"publisher","first-page":"5012","DOI":"10.1200\/JCO.2024.42.16_suppl.5012","volume":"42","author":"RR Aggarwal","year":"2024","unstructured":"Aggarwal\u00a0RR, Rottey\u00a0S, Bernard-Tessier\u00a0A et\u00a0al (2024) Phase\u00a01b\u00a0study\u00a0of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC). JCO 42:5012\u20135012","journal-title":"JCO"},{"key":"2511_CR4","unstructured":"Anonymous Deutsche Gesellschaft f\u00fcr Urologie. S3-Leitlinie Prostatakarzinom, Vertion 7.0"},{"key":"2511_CR5","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","volume":"19","author":"AM Aparicio","year":"2013","unstructured":"Aparicio\u00a0AM, Harzstark\u00a0AL, Corn\u00a0PG et\u00a0al (2013) Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer. Clin Cancer Res 19:3621\u20133630","journal-title":"Clin Cancer Res"},{"key":"2511_CR6","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","volume":"22","author":"AM Aparicio","year":"2016","unstructured":"Aparicio\u00a0AM, Shen\u00a0L, Tapia\u00a0EL et\u00a0al (2016) Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clin Cancer Res 22:1520\u20131530","journal-title":"Clin Cancer Res"},{"key":"2511_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.18632\/oncotarget.26523","volume":"10","author":"L Apostolidis","year":"2019","unstructured":"Apostolidis\u00a0L, Nientiedt\u00a0C, Winkler\u00a0EC et\u00a0al (2019) Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. Oncotarget 10:17\u201329","journal-title":"Oncotarget"},{"key":"2511_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1200\/JCO.2024.42.4_suppl.121","volume":"42","author":"H Beltran","year":"2024","unstructured":"Beltran\u00a0H, Dowlati\u00a0A, Jain\u00a0P et\u00a0al (2024) Interim results from a\u00a0phase\u00a01\/2\u00a0study of HPN328, a\u00a0tri-specific, half-life (T1\/2) extended DLL3-targeting T\u2011cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN). JCO 42:121\u2013121","journal-title":"JCO"},{"key":"2511_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-18-1912","volume":"25","author":"H Beltran","year":"2019","unstructured":"Beltran\u00a0H, Oromendia\u00a0C, Danila\u00a0DC et\u00a0al (2019) A Phase\u00a0II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clin Cancer Res 25:43\u201351","journal-title":"Clin Cancer Res"},{"key":"2511_CR10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","volume":"1","author":"H Beltran","year":"2011","unstructured":"Beltran\u00a0H, Rickman\u00a0DS, Park\u00a0K et\u00a0al (2011) Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 1:487\u2013495","journal-title":"Cancer Discov"},{"key":"2511_CR11","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41391-022-00524-7","volume":"25","author":"LC Brown","year":"2022","unstructured":"Brown\u00a0LC, Halabi\u00a0S, Somarelli\u00a0JA et\u00a0al (2022) A phase\u00a02\u00a0trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer. Prostate Cancer Prostatic Dis 25:762\u2013769","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2511_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","volume":"121","author":"V Conteduca","year":"2019","unstructured":"Conteduca\u00a0V, Oromendia\u00a0C, Eng\u00a0KW et\u00a0al (2019) Clinical features of neuroendocrine prostate cancer. Eur J Cancer 121:7\u201318","journal-title":"Eur J Cancer"},{"key":"2511_CR13","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/S1470-2045(19)30408-5","volume":"20","author":"PG Corn","year":"2019","unstructured":"Corn\u00a0PG, Heath\u00a0EI, Zurita\u00a0A et\u00a0al (2019) Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a\u00a0randomised, open-label, phase\u00a01-2\u00a0trial. Lancet Oncol 20:1432\u20131443","journal-title":"Lancet Oncol"},{"key":"2511_CR14","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.juro.2007.05.044","volume":"178","author":"S Culine","year":"2007","unstructured":"Culine\u00a0S, El Demery\u00a0M, Lamy\u00a0PJ et\u00a0al (2007) Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J\u00a0Urol 178:844\u2013848 (discussion 848)","journal-title":"J Urol"},{"key":"2511_CR15","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1517\/13543784.15.7.815","volume":"15","author":"L Feun","year":"2006","unstructured":"Feun\u00a0L, Savaraj\u00a0N (2006) Pegylated arginine deiminase: a\u00a0novel anticancer enzyme agent. Expert Opin Investig Drugs 15:815\u2013822","journal-title":"Expert Opin Investig Drugs"},{"key":"2511_CR16","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1093\/annonc\/mdr004","volume":"22","author":"A Fl\u00e9chon","year":"2011","unstructured":"Fl\u00e9chon\u00a0A, Pouessel\u00a0D, Ferlay\u00a0C et\u00a0al (2011) Phase\u00a0II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Oncol 22:2476\u20132481","journal-title":"Ann Oncol"},{"key":"2511_CR17","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland\u00a0SJ, De Almeida\u00a0LM, De Giorgi\u00a0U et\u00a0al (2023) Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N\u00a0Engl J Med 389:1453\u20131465","journal-title":"N Engl J Med"},{"key":"2511_CR18","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/pros.24497","volume":"83","author":"LS Graham","year":"2023","unstructured":"Graham\u00a0LS, Haffner\u00a0MC, Sayar\u00a0E et\u00a0al (2023) Clinical, pathologic, and molecular features of amphicrine prostate cancer. Prostate 83:641\u2013648","journal-title":"Prostate"},{"key":"2511_CR19","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1172\/JCI128212","volume":"129","author":"MP Labrecque","year":"2019","unstructured":"Labrecque\u00a0MP, Coleman\u00a0IM, Brown\u00a0LG et\u00a0al (2019) Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J\u00a0Clin Invest 129:4492\u20134505","journal-title":"J Clin Invest"},{"key":"2511_CR20","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/annonc\/mdn694","volume":"20","author":"Y Loriot","year":"2009","unstructured":"Loriot\u00a0Y, Massard\u00a0C, Gross-Goupil\u00a0M et\u00a0al (2009) Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a\u00a0prospective study evaluating also neuroendocrine features. Ann Oncol 20:703\u2013708","journal-title":"Ann Oncol"},{"key":"2511_CR21","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1158\/0008-5472.CAN-23-0593","volume":"83","author":"A Lundberg","year":"2023","unstructured":"Lundberg\u00a0A, Zhang\u00a0M, Aggarwal\u00a0R et\u00a0al (2023) The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer. Cancer Res 83:2763\u20132774","journal-title":"Cancer Res"},{"key":"2511_CR22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13046-022-02255-y","volume":"41","author":"L Merkens","year":"2022","unstructured":"Merkens\u00a0L, Sailer\u00a0V, Lessel\u00a0D et\u00a0al (2022) Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation. J\u00a0Exp Clin Cancer Res 41:46","journal-title":"J Exp Clin Cancer Res"},{"key":"2511_CR23","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","volume":"174","author":"DA Quigley","year":"2018","unstructured":"Quigley\u00a0DA, Dang\u00a0HX, Zhao\u00a0SG et\u00a0al (2018) Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell 174:758\u2013769.e759","journal-title":"Cell"},{"key":"2511_CR24","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1080\/028418602321028292","volume":"41","author":"G Steineck","year":"2002","unstructured":"Steineck\u00a0G, Reuter\u00a0V, Kelly\u00a0WK et\u00a0al (2002) Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements. Acta Oncol 41:668\u2013674","journal-title":"Acta Oncol"},{"key":"2511_CR25","doi-asserted-by":"crossref","unstructured":"Taplin M\u2011E, Bubley GJ, Shuster TD et\u00a0al Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer. N\u00a0Engl J Med 332:1393\u20131398","DOI":"10.1056\/NEJM199505253322101"},{"key":"2511_CR26","doi-asserted-by":"publisher","first-page":"S975","DOI":"10.1016\/j.annonc.2024.08.1697","volume":"35","author":"SH Tolmeijer","year":"2024","unstructured":"Tolmeijer\u00a0SH, Kwan\u00a0EM, Ng\u00a0SWS et\u00a0al (2024) 1616P Circulating tumour DNA (ctDNA) measurements and PET-imaging to evaluate response in a\u00a0phase\u00a0Ib trial of metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177-PSMA-617 (LuPSMA) plus pembrolizumab (PRINCE). Ann Oncol 35:S975\u2013S976","journal-title":"Ann Oncol"},{"key":"2511_CR27","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.1158\/1078-0432.CCR-15-0744","volume":"21","author":"H Tsai","year":"2015","unstructured":"Tsai\u00a0H, Morais\u00a0CL, Alshalalfa\u00a0M et\u00a0al (2015) Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. Clin Cancer Res 21:5619\u20135629","journal-title":"Clin Cancer Res"},{"key":"2511_CR28","doi-asserted-by":"publisher","first-page":"14948","DOI":"10.3390\/ijms232314948","volume":"23","author":"G Von Amsberg","year":"2022","unstructured":"Von Amsberg\u00a0G, Zilles\u00a0M, Mansour\u00a0W et\u00a0al (2022) Salvage Chemotherapy with Cisplatin, Ifosfamide, and Paclitaxel in Aggressive Variant of Metastatic Castration-Resistant Prostate Cancer. Int J Mol Sci 23:14948","journal-title":"Int J Mol Sci"},{"key":"2511_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","volume":"23","author":"Y Yamada","year":"2021","unstructured":"Yamada\u00a0Y, Beltran\u00a0H (2021) Clinical and Biological Features of Neuroendocrine Prostate Cancer. Curr Oncol Rep 23:15","journal-title":"Curr Oncol Rep"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02511-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-024-02511-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02511-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T17:52:05Z","timestamp":1741629125000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-024-02511-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2511"],"URL":"https:\/\/doi.org\/10.1007\/s00120-024-02511-3","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"assertion":[{"value":"18 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"G.\u00a0von Amsberg: 1.\u00a0Anstellungsverh\u00e4ltnis oder F\u00fchrungsposition: nein; 2.\u00a0Beratungs- bzw. Gutachtert\u00e4tigkeit, Advisory Boards: Roche, BMS, Astellas, Sanofi, Janssen, MSD, Merck, Pfizer, Bayer, Amgen, EISAI, Novartis, Lilly, AstraZeneca, Ipsen; 3.\u00a0Besitz von Gesch\u00e4ftsanteilen, Aktien oder Fonds: nein. 4.\u00a0Patent, Urheberrecht, Verkaufslizenz: nein; 5.\u00a0Honorare\/Vortr\u00e4ge\/Reisekosten\/Kongressunterst\u00fctzung Roche, BMS, Astellas, Sanofi, Janssen, MSD, Merck, Pfizer, Bayer, Amgen, EISAI, AstraZeneca, Ipsen; 6.\u00a0Finanzierung wissenschaftlicher Untersuchungen im Rahmen Industrie-gesponserter Studien (Roche, BMS, MSD, AstraZeneca, Sanofi, Lilly, EISAI, Amgen, AvenCell, Ipsen, GILEAD); 7.\u202f+\u20098.\u00a0Andere finanzielle Beziehungen und immaterielle Interessenkonflikte: nein. S.\u00a0Dyshlovoy und M.\u00a0Kaune geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}